U.S. Markets closed

Cesca Therapeutics Inc. (KOOL)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.15+0.07 (+2.27%)
At close: 4:00PM EDT
People also watch
CYTXOPXACURPSTIOSIR
  • 8K filed today. Does it mean they are trying to avoid takeover? Don't know if I'm reading it right way, can
    someone elaborate that knows more about these filings.
  • Some people are always grumbling because beautiful roses have thorns.http://dataunion.tistory.com/9474

    ThermoGenesis Corp NASDAQ $KOOL Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0 In other words, the correlation coefficient of the other stocks
    dataunion.tistory.com
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states:
    • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence late 2017
    • Sales and or licensing agreement/s could be very significant and fast
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

    Clyra Medical | Make Life Better
    www.clyramedical.com
  • I thought the earnings weren't that bad(correct me if I'm wrong). Seems like new management knows what they're
    doing. Matter of time.
  • Preview of Today's Report:
    1-Another loss reported
    2-Promises made (same ole, same ole)
    3-Notification of more bonuses and stock options for leadership
  • little volume movement will put this on 7to 8 imo
  • Michael feel same way about stock. What is your opinion as to the upside of stock if they do get approval and bring to market.
    So little shares in float and high short interest.
  • Stock is a HUGE home run bu twill take some time. The issue I think is the brain surgeons at the FDA cant figure out how to run a test cause it is not a drug. They basically spin the blood and then reinject the stem cells to regrow circulatory function. apparently saving a leg from amputation is not a good enough endpoint so they will measure oxygen level increases in the blood
  • smell huge action comming.
  • Does anyone know what the cost of the blood infusion might be? Perhaps that has dulled the enthusiasm for a remarkable study result?
  • Quick profit takers
    Will continue up ! (Should anyway )
  • MONSTER NEWS WITHIN DAYS...2000%++ UPSIDE POTENTIAL

    AQSZF (MC $15 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $15 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch...
    The Company expects to report topline results from this multi-dose study in the first quarter of 2017.

    Market Cap :US$ 15 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.21

    Great Video
    https://www.youtube.com/watch?v=jV00WmYBtv4

    Presentation
    http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf

    AQS1301 topline results in 1Q 2017

    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018

    Aequus Pharmaceuticals
    Aequus has an expanding product pipeline of drugs in Canada. Revenues and cash flows are increasing and products produce a 50% margin, Edward Karr, Managing ...
    www.youtube.com
  • Interesting close!
  • All 18 had significant reduction in the size of their wound. That's unheard of in such studies. Will this be fast tracked for approval?
  • Surprised this isn't moving up more, these results are extremely positive. I expect it will climb for a couple of days once people realize just how positive these results are
  • Stop advertising websites and newsletters here. This board is for sharing insights about Cesca.
  • KOOL should go up 50% to 100% later today. watch closely.
  • Gonna pop
  • It is clear from the current neutral institutional ownership of 12.30% that KOOL could yield both a pullback or an uptick. The scenarios are quite interesting at current levels. Ive been struggling with this stock lately. Some of my other trades have been from awe-someSTOCKS which are working out pretty well.
  • T0pMarketGaIners.c0m is one of the best “alerts” services I have found. Just sign up and watch from the sidelines, you will see!